Genetic test-guided treatment for advanced bile and liver cancers
Part of Cancer, Digestive system clinical trials.
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65 and can give informed consent.
- You have stage IV hepatobiliary cancer confirmed by imaging and biopsy/pathology.
- You are choosing palliative care as the main approach (focus on comfort and control).
- Your genetic test must show a gene mutation that has a currently approved targeted medicine in China or the US.
- Your general health and daily functioning is fairly good (ECOG 0 to 2), and you’re expected to live at least 3 months.
- You must not meet major exclusions like severe organ problems, uncontrolled infections, or certain brain/heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests whether treatments chosen based on the specific gene changes in your bile duct cancer can work better. It's for people with advanced cancer that hasn't responded to standard therapy.
This trial looks at how well a modern genetic test (next-generation sequencing) works when analyzing tissue samples from people with bile duct cancer. The goal is to see if this test can help doctors better understand these tumors.
This early-phase trial tests a new kind of gene therapy (called HNF4α srRNA) given through a vein for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that has stopped responding to standard chemotherapy. The goal is to see if it is safe and if it can help slow or stop the cancer.
This study tests if early genetic testing of your tumor can help find targeted treatments for advanced cancers that are hard to treat, such as pancreatic, liver, or triple-negative breast cancer. It aims to match you with a therapy based on your tumor's genetic profile.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.